ACADIA Pharmaceuticals Inc.

As of June 30, 2026, ACADIA Pharmaceuticals Inc. carries a market capitalization of 66.58B, placing it among publicly traded companies globally. Its enterprise value stands at 51.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ACADIA Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, ACADIA Pharmaceuticals Inc. has 172.13M shares outstanding.

As of June 30, 2026, ACADIA Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 9.90. The price-to-sales ratio is 3.31, and the price-to-book ratio stands at 2.92.

As of June 30, 2026, ACADIA Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 29.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 51.16B versus a market cap of 66.58B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ACADIA Pharmaceuticals Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, ACADIA Pharmaceuticals Inc. posted a return on equity (ROE) of 35.74, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 25.64, measuring how efficiently the asset base is converted into earnings. The company generates approximately 26.11M in revenue per employee across its workforce of 762.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.45 indicates how many times ACADIA Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ACADIA Pharmaceuticals Inc. recorded an income tax benefit of -4.53B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 2.12B, leaving 6.65B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, ACADIA Pharmaceuticals Inc. generated 19.89B in revenue and converted that into 6.65B in net income, yielding earnings per share of 38.67. EBITDA reached 1.72B, while operating income came in at 1.51B.

As of June 30, 2026, ACADIA Pharmaceuticals Inc. holds 16.71B in cash and equivalents against 1.29B in total debt, resulting in a net debt position of -6.73B. Total book value stands at 22.83B, with working capital of 15.08B providing operational flexibility.

ACADIA Pharmaceuticals Inc. produced 2.80B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -256.73M in capital expenditures, free cash flow totaled 2.54B - equivalent to 14.96 per share.

Over the twelve months ended June 30, 2026, ACADIA Pharmaceuticals Inc. posted a gross margin of 91.13, reflecting its pricing power and cost economics. The operating margin of 7.59 and net profit margin of 33.42 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.83, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.23, meaning ACADIA Pharmaceuticals Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, ACADIA Pharmaceuticals Inc. has an Altman Z-Score of 5.22, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.